8-KLeadership Changes

AMGEN INC 8-K Report, Executive Changes (May 19, 2026)

Filed May 19, 2026For Securities:AMGN

Summary

Amgen Inc. has announced a significant leadership transition in its finance department. Peter H. Griffith, the current Executive Vice President and Chief Financial Officer (CFO), will retire from his executive role effective August 31, 2026. He will remain with the company in a non-executive officer capacity until January 31, 2027, to ensure a smooth handover and will receive his entitled retirement benefits. The company has appointed Thomas Dittrich, age 62, as the new Executive Vice President and CFO, effective September 1, 2026. Mr. Dittrich will initially join Amgen in a non-executive role from July 1, 2026, to August 31, 2026, based in Rotkreuz, Switzerland, before relocating to Thousand Oaks, California. Mr. Dittrich brings extensive financial leadership experience from his previous roles, including CFO at Galderma Group AG and Shire Pharmaceuticals, and notably, he previously worked at Amgen in senior finance positions.

Key Highlights

  • 1Peter H. Griffith is retiring as CFO effective August 31, 2026, with a transition period until January 31, 2027.
  • 2Thomas Dittrich appointed as the new Executive Vice President and Chief Financial Officer, effective September 1, 2026.
  • 3Mr. Dittrich will have an initial non-executive role from July 1, 2026, to August 31, 2026.
  • 4Mr. Dittrich's compensation package includes a substantial base salary (CHF 1,070,000), annual incentive targets, and significant long-term equity awards (options, RSUs, performance units) totaling CHF 4,500,000 for fiscal 2026.
  • 5To compensate for foregone compensation, Mr. Dittrich will receive a one-time RSU award (CHF 4,700,000) and a one-time cash bonus (CHF 4,000,000).
  • 6A two-year retention bonus of CHF 5,800,000 is also included, subject to repayment if Mr. Dittrich resigns or is terminated for cause within two years.
  • 7Mr. Dittrich has prior experience at Amgen, serving as VP of Finance Corporate Planning and Chief Accounting Officer.

Frequently Asked Questions

This filing primarily announces the retirement of Amgen's Chief Financial Officer, Peter H. Griffith, and the appointment of his successor, Thomas Dittrich.

Mr. Dittrich's compensation includes a base salary of CHF 1,070,000 annually, a target annual incentive of 100% of base salary, significant long-term equity awards valued at CHF 4,500,000 for fiscal 2026, and one-time awards for foregone compensation (CHF 4,700,000 in RSUs and CHF 4,000,000 cash bonus). He also has a CHF 5,800,000 retention bonus and relocation benefits.

Mr. Dittrich has extensive financial leadership experience, most recently as CFO of Galderma Group AG. He previously served as CFO of Shire Pharmaceuticals and held senior finance roles at Sulzer AG. Notably, he has prior experience with Amgen, having served as VP, Finance Corporate Planning and Chief Accounting Officer.

Yes, Mr. Griffith will remain employed by Amgen as an Executive Vice President in a non-executive officer position from September 1, 2026, until January 31, 2027, to facilitate the transition. He is retirement eligible and will receive benefits according to company plans.